Risk of diabetes in patients treated with HMG-CoA reductase inhibitors

Metabolism: Clinical and Experimental

Volumn 64, Issue 4, 2015, Pages 482-488

  Cho, Yongin ^a   Choe, Eunyeong ^b   Lee, Yong Ho ^a   Seo, Ji Won ^a   Choi, Younjeong ^a   Yun, Yujung ^a   Wang, Hye Jin ^a   Ahn, Chul Woo ^a   Cha, Bong Soo ^a   Lee, Hyun Chul ^a   Kang, Eun Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b International St Mary's Hospital   (South Korea)

Author keywords

Diabetes mellitus; HMG CoA reductase inhibitors; Hypercholesterolemia; Statin

Indexed keywords

ATORVASTATIN; GLUCOSE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BODY MASS; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; AGED; COMPARATIVE STUDY; COMPLICATION; RETROSPECTIVE STUDY;

AGED; DIABETES MELLITUS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; PYRIMIDINES; PYRROLES; QUINOLINES; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; SULFONAMIDES;

EID: 84923582249     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.09.008     Document Type: Article

References (37)

1. A.M. Gotto, and J.E. Moon Management of cardiovascular risk: the importance of meeting lipid targets Am J Cardiol 110 2012 3A 14A
2. P.M. Ridker, E. Danielson, and F. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
3. P.S. Sever, B. Dahlöf, and N.R. Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Drugs 64 2004 43 60
4. R. Collins, J. Armitage, S. Parish, P. Sleigh, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
5. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
6. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
7. D.J. Freeman, J. Norrie, and N. Sattar Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
8. E.P. Navarese, A. Buffon, and F. Andreotti Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus Am J Cardiol 111 2013 1123 1130
9. A.A. Carter, T. Gomes, X. Camacho, D.N. Juurlink, B.R. Shah, and M.M. Mamdani Risk of incident diabetes among patients treated with statins: population based study BMJ 346 2013 f2610
10. N.L. Zaharan, D. Williams, and K. Bennett Statins and risk of treated incident diabetes in a primary care population Br J Clin Pharmacol 75 2013 1118 1124
11. C.-K. Yoon Drug Utilization Review (DUR) policy of government and directivity J Korean Med Assoc 53 2010 544 547
12. M. Mamdani, K. Sykora, and P. Li Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding BMJ 330 2005 960 962
13. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
14. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
15. M.B. Rocco Statins and diabetes risk: fact, fiction, and clinical implications Cleve Clin J Med 79 2012 883 893
16. A.L. Culver, I.S. Ockene, and R. Balasubramanian Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative Arch Intern Med 172 2012 144 152
17. J. Bełtowski, G. Wójcicka, and A. Jamroz-Wis̈niewska Adverse effects of statins - mechanisms and consequences Curr Drug Saf 4 2009 209 228
18. M. Brault, J. Ray, Y.-H. Gomez, C.S. Mantzoros, and S.S. Daskalopoulou Statin treatment and new-onset diabetes: a review of proposed mechanisms Metabolism 63 2014 735 745
19. F. Xia, L. Xie, and A. Mihic Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic β-cells Endocrinology 149 2008 5136 5145
20. H. Mulder, and C. Ling Mitochondrial dysfunction in pancreatic β-cells in type 2 diabetes Mol Cell Endocrinol 297 2009 34 40
21. H.-B. Kwak, A. Thalacker-Mercer, and E.J. Anderson Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes Free Radic Biol Med 52 2011 198 207
22. C.M. Kusminski, and P.E. Scherer Mitochondrial dysfunction in white adipose tissue Trends Endocrinol Metab 23 2012 435 443
23. M. Nakata, S. Nagasaka, I. Kusaka, H. Matsuoka, S. Ishibashi, and T. Yada Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control Diabetologia 49 2006 1881 1892
24. M.E. Khamseh, M. Malek, R. Aghili, and Z. Emami Sarcopenia and diabetes: pathogenesis and consequences Br J Diabetes Vasc Dis 11 2011 230 234
25. A. Draeger, K. Monastyrskaya, and M. Mohaupt Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia J Pathol 210 2006 94 102
26. B.A. Golomb, M.A. Evans, J.E. Dimsdale, and H.L. White Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial Arch Intern Med 172 2012 1180 1182
27. M. Hafner, P. Juvan, T. Rezen, K. Monostory, J.M. Pascussi, and D. Rozman The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action Pharmacogenet Genomics 21 2011 741 750
28. H. Fujino, I. Yamada, S. Shimada, T. Nagao, and M. Yoneda Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyllutaryl coenzyme A reductase Arzneimittelforschung 52 2011 745 753
29. T. Maejima, T. Sugano, and H. Yamazaki Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells J Pharmacol Sci 116 2011 107 115
30. T. Maejima, H. Yamazaki, and T. Aoki Effect of pitavastatin on apolipoprotein AI production in HepG2 cell Biochem Biophys Res Commun 324 2004 835 839
31. A. Saiki, T. Murano, F. Watanabe, T. Oyama, Y. Miyashita, and K. Shirai Pitavastatin enhanced lipoprotein lipase expression in 3 T3-L1 preadipocytes J Atheroscler Thromb 12 (Suppl. 1) 2005 163 168
32. L. Masana Pitavastatin in cardiometabolic disease: therapeutic profile Cardiovasc Diabetol 12 2013 S2
33. N. Hounslow, P. Robillard, M. Suzuki, P. Betting, P. Giral, and M. Chapman Pitavastatin is without effect on glycaemic parameters in metabolic syndrome (CAPITAIN Study) 2012 World Congress of Diabetes Madrid
34. T. Mita, S. Nakayama, and H. Abe Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia J Diabetes Invest 4 2013 297 303
35. T. Yamakawa, T. Takano, S.-i. Tanaka, K. Kadonosono, and Y. Terauchi Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus J Atheroscler Thromb 15 2008 269 275
36. D. Preiss, S.R.K. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA 305 2011 2556 2564
37. J. Shepherd, P. Barter, and R. Carmena Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study Diabetes Care 29 2006 1220 1226